Recruiting
Early Phase 1

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Sponsor:

Canadian Cancer Trials Group

Code:

NCT04161248

Conditions

Lymphoma, B-Cell

Eligibility Criteria

Sex: All

Age: 16 - 65

Healthy Volunteers: Not accepted

Interventions

Venetoclax

Rituximab Injection

Rituximab SC

Gemcitabine

Dexamethasone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information